The latest news and breakthrough developments from the field of cancer research. We bring you the latest updates from organisations looking into diagnosing and treating all types of cancers using the latest scientific advancements and what is being done to improve patient care.
Research institutes have committed £5.5 million in funding for a world-leading research team tasked with making personalised medicines for bowel cancer patients.
A scarcity of suitable therapies and geographic disparities in access to care are impacting survival rates for children with cancer; Lorna Rothery spoke to the European branch of Childhood Cancer International, a pan-European organisation committed to improving outcomes for children and adolescents affected by cancer.
Researchers suggest that microwave ablation, a minimally invasive procedure, could offer comparable progression-free survival rates to surgery with fewer complications.
A minimally invasive treatment for prostate cancer, using a combination of MRI and transurethral ultrasound, has shown effectiveness in a recent study.
Dr Alice Di Pasquale, Scientific Research Officer at Breast Cancer UK, explains why more must be done to increase awareness of Endocrine Disrupting Chemicals and breast cancer risk.
Researchers have identified 140 genes that could change how non-small cell lung cancer (NSCLC) patients are treated with immunotherapy and low-dose radiation.
Paul Landau, CEO of Careology, a digital cancer care platform used by the NHS and private health sector, posits the need for smart investment into digital tools to support cancer care and maximise the efficiency of resources.
The past ten years have seen significant progress in cancer care, detecting cancers earlier and managing them more successfully and less invasively on a global scale.
Is there a way to mend a broken heart? Biomedical engineers have found a potential way to mend a broken heart using a genetic mutation commonly associated with skin cancers.
Secarna Pharmaceuticals, the next-generation antisense drug discovery and development company, is developing novel approaches to successfully target Neuropilin 1 (NRP1), a promising target for the treatment of cancer.
